Literature DB >> 17885729

Preemptive treatment of fungal infection based on plasma (1 --> 3)beta-D-glucan levels after liver transplantation.

N Akamatsu1, Y Sugawara, J Kaneko, S Tamura, M Makuuchi.   

Abstract

BACKGROUND: Invasive fungal infection remains a major challenge in liver transplantation and the mortality rate is high. Early diagnosis and treatment are required for better results. PATIENTS: We prospectively measured plasma (1 --> 3)beta-D-glucan (BDG) levels in 180 living donor liver transplant recipients for 1 year after surgery. Fungal infection was defined as proposed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group. Preemptive treatment (intravenous fluconazole and trimethoprim-sulfamethoxazole) was started when the BDG level was greater than 40 pg/ml.
RESULTS: Twenty-four patients (13%) were diagnosed with invasive fungal infection. The responsible pathogens included Candida spp. in 14 cases, Aspergillus fumigatus in 5, Cryptococcus neoformans in 3, and Pneumocystis jiroveci in 2. Preemptive treatment was performed in 22% of patients (n = 40). Renal impairment and mild gastrointestinal intolerance due to the drugs were observed in 28% (11/40) of patients during treatment. Among them 14 patients were diagnosed with fungal infection including seven candidiasis, five aspergillosis, and two Pneumocystis jiroveci pneumonia. The sensitivity and specificity of BDG for overall fungal infection was 58% and 83%, respectively, with a positive predictive value of 35% and a negative predictive value of 93%, and a positive likelihood ratio of 3.41 and a negative likelihood ratio of 1.98. The overall mortality for fungal infection in our series was 0.6%.
CONCLUSION: Although the sensitivity and positive predictive value were low, the low mortality rate after fungal infection and the mild side effects of the preemptive treatment might justify our therapeutic strategy. Based on the effectiveness, this strategy warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885729     DOI: 10.1007/s15010-007-6240-7

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  24 in total

Review 1.  Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis.

Authors:  Akira Onishi; Daisuke Sugiyama; Yoshinori Kogata; Jun Saegusa; Takeshi Sugimoto; Seiji Kawano; Akio Morinobu; Kunihiro Nishimura; Shunichi Kumagai
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation.

Authors:  Barbara D Alexander; P Brian Smith; R Duane Davis; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

3.  Prophylaxis of invasive mycoses in solid organ transplantation.

Authors:  Kyle P Radack; Barbara D Alexander
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 4.  Overcoming antifungal resistance.

Authors:  Anand Srinivasan; Jose L Lopez-Ribot; Anand K Ramasubramanian
Journal:  Drug Discov Today Technol       Date:  2014-03

5.  Contribution of (1,3)-beta-D-glucan to diagnosis of invasive candidiasis after liver transplantation.

Authors:  E Levesque; S El Anbassi; E Sitterle; F Foulet; J C Merle; F Botterel
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

6.  Maitake beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse.

Authors:  Hong Lin; Elisa De Stanchina; Xi Kathy Zhou; Yuhong She; Danthanh Hoang; Sandy Wy Cheung; Barrie Cassileth; Susanna Cunningham-Rundles
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-14

7.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

8.  Levels of (1→3)-β-D-glucan, Candida mannan and Candida DNA in serum samples of pediatric cancer patients colonized with Candida species.

Authors:  Eiman Mokaddas; Mona H A Burhamah; Zia U Khan; Suhail Ahmad
Journal:  BMC Infect Dis       Date:  2010-10-06       Impact factor: 3.090

9.  Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan: a bivariate meta-analysis and systematic review.

Authors:  Wei-Jie Li; Ya-Ling Guo; Tang-Juan Liu; Ke Wang; Jin-Liang Kong
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

10.  Detection of (1, 3)-β-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts.

Authors:  Elitza S Theel; Deborah J Jespersen; Seher Iqbal; Jean E Bestrom; Leonard O Rollins; Lori J Misner; Barbara J Markley; Jayawant Mandrekar; Larry M Baddour; Andrew H Limper; Nancy L Wengenack; Matthew J Binnicker
Journal:  Mycopathologia       Date:  2012-09-01       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.